| Name | Nelfinavir Mesylate |
| Description | Nelfinavir Mesylate (Viracept) is an effective HIV protease inhibitor (Ki: 2 nM). |
| Kinase Assay | GTPγ[35S] binding assay: The cells are homogenized and centrifuged at 26900 × g for 30 min at 4°C. Membranes are re-suspended in 20 mM HEPES (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA and 0.1% fat-free BSA at 2–3 mg protein/mL. GTPγ[35S] binding assay is performed with the membranes (75 mg protein /mL in 50 mM HEPES, 100 mM NaCl, 10 mM MgCl2, 20 μg/mL saponin and 0.1% fat-free BSA (pH 7.4), 5 mg/mL with wheat-germ agglutinin-coated scintillation proximity assay-bead, and 10 μM GDP for 10–15 min. The GTPγ[35S]-binding reaction is started by the addition of 200 pM GTPγ[35S]. After 120 min at room temperature, the plates are centrifuged for 10 min at 300 × g and counted. |
| Storage | keep away from direct sunlight,store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 93 mg/mL (140.1 mM)
Ethanol : 93 mg/mL (140.1 mM)
|
| Keywords | AG-1343 | proliferation | HIV Protease | HIV | protease | Nelfinavir | cells | infection | Human immunodeficiency virus | multiple | Nelfinavir Mesylate | inhibit | phosphorylation | AG-1343 Mesylate | AG 1343 | AG1343 Mesylate | Inhibitor | production | myeloma |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Kaempferol | Dolutegravir intermediate-1 | Dextran sulfate sodium salt (MW 4500-5500) | Lamivudine | Chloroquine phosphate | Decanedioic acid | Tenofovir |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
